Formulation and Evaluation of Bilayer Tablets of Metoclopramide Hydrochloride and Diclofenac Sodium

Abstract

Migraine is a type of recurring headache of moderate to severe intensity associated with gastrointestinal, neurological, and autonomic symptoms. In migraine, a combination of pretreatment with antiemetics is required for symptomatic treatment, when nausea and vomiting are severe. In our present research, we have selected the metoclopramide hydrochloride (MTH) active ingredient for study because it has an antiemetic effect and is a prokinetic agent. MTH is more effective to counteract gastric stasis associated with migraine, and it enhances the rate of absorption of non-steroidal anti-inflammatory drugs (NSAIDs). In the present investigation we combine MTH and a second active ingredient, diclofenac sodium, as a formulated bilayer tablet to prevent degradation of MTH.

<p>Metoclopramide nanoparticles modulate immune response in a diabetic rat model: association with regulatory T cells and proinflammatory cytokines</p>

“…The thermal behavior of the physical mixture of BSA and MCA (1:1) in the absence of glutaraldehyde exhibited characteristic endothermic peaks of both MCA and BSA, confirming absence of any interaction ( Figure 4B). These characteristic endothermic peaks of MCA (at 95°C, 158°C, and 185°C) correspond to melting of the hydrated form, recrystallization of an anhydrous form, and final melting, respectively, [30][31][32] and the characteristic endothermic peaks of BSA (69°C and 210°C) correspond to its melting ( Figure 4B). 25,33 However, thermography of BSA/MCA NPs did not show characteristic endothermic peaks of BSA or MCA, but new peaks appeared, indicating the interaction between NP components and cross-linking of BSA molecules using glutaraldehyde (cross-linker), where it is known that glutaraldehyde changes the thermal properties and crystallization temperatures of compounds.…”